Copyright
©The Author(s) 2022.
World J Clin Cases. May 16, 2022; 10(14): 4334-4347
Published online May 16, 2022. doi: 10.12998/wjcc.v10.i14.4334
Published online May 16, 2022. doi: 10.12998/wjcc.v10.i14.4334
Figure 1 Broad guidance for Wilson’s disease workup interpretation.
1Only valid if holo-ceruloplasmin is calculated with an enzymatic test. 2Higher probability/3Lower probability of overtreatment or non-compliance. 4Non-compliant patients who take DPA on the day of the 24 h urinary collection; UCE in non-compliant patients who do not take DPA > 48 h prior to the assessment should be interpreted as D-penicillamine 48 h cessation test results. 5UZE < 2 mg/24 h in non-compliance/UZE >2 mg/24 h in non-response. DPA: D-penicillamine; DPA CT: D-penicillamine 48 h cessation test; NCC: Non-ceruloplamin-bound copper; UCE: Urinary copper excretion; UZE: Urinary zinc excretion.
- Citation: Lynch EN, Campani C, Innocenti T, Dragoni G, Forte P, Galli A. Practical insights into chronic management of hepatic Wilson’s disease. World J Clin Cases 2022; 10(14): 4334-4347
- URL: https://www.wjgnet.com/2307-8960/full/v10/i14/4334.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i14.4334